<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308443">
  <stage>Registered</stage>
  <submitdate>22/12/2009</submitdate>
  <approvaldate>21/06/2005</approvaldate>
  <actrnumber>ACTRN12610000015044</actrnumber>
  <trial_identification>
    <studytitle>Preemptive therapy vs valacyclovir prophylaxis for cytomegalovirus (CMV) disease after renal transplantation</studytitle>
    <scientifictitle>A randomised study comparing universal valacyclovir prophylaxis with quantitative polymerase chain reaction (PCR) based preemptive therapy for cytomegalovirus (CMV) disease in renal transplant recipients.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRG050600003
Cochrane Renal Group</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cytomegalovirus disease in renal transplant recipients</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Preemptive therapy in the case of significant positivity of PCR for CMV deoxyribonucleic acid (DNA) (&gt;2000 copies/ml) - oral valganciclovir (Valcyte, Hoffman-La Roche, Germany) 900mg twice per day until clearance of CMV viremia (negative result of PCR for CMV DNA) or for a minimum of 14 days commenced during first year post-transplant.</interventions>
    <comparator>Universal prophylaxis (to all patients in comparator group): oral valacyclovir (Valtrex, Glaxo Wellcome, UK) 2g four times per day for 3 months started within 1 week post-transplant (= the control group)</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cumulative incidence of CMV disease (defined by clinical symptoms + presence of CMV viremia by quantitative PCR CMV DNA test)</outcome>
      <timepoint>12 months post transplant</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>acute rejection (clinical + subclinical) diagnosed by renal allograft biopsy</outcome>
      <timepoint>12 months post transplant</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Histologically proven interstitial fibrosis/tubular atrophy of the allograft, expression of messenger ribonucleic acid (mRNA) cytokines intragraft included</outcome>
      <timepoint>36 months post transplant</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative incidence of CMV infection (viremia), intragraft CMV included (defined by positive PCR for CMV DNA in blood or renal allograft biopsy specimen)</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>other infections assessed by clinical symptoms, microbiological cultures, blood tests</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative patient and graft survival based on prospective observation</outcome>
      <timepoint>12 moths post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>adverse events based on prospective observation (examples od side effects - heamatological - leukopenia, trombocytopenia, anemia, psychiatric - hallucinations+confusion, liver enzyme abnormalities, de novo post transplant diabetes, de novo malignancy, etc.)</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>renal function assessed by serum creatinine and estimated glomerular filtration rate</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>delayed graft function (defined by the need of dialysis within first week post transplant)</outcome>
      <timepoint>1 week post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>renal function assessed by serum creatinine and estimated glomerular filtration rate</outcome>
      <timepoint>36 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative patient and graft survival based on prospective observation</outcome>
      <timepoint>36 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>chronic rejection (humoral/cellular) diagnosed by renal allograft biopsy</outcome>
      <timepoint>36 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>other infections assessed by clinical symptoms, microbiological cultures, blood tests</outcome>
      <timepoint>36 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Late onset CMV disease (defined by clinical symptoms + presence of CMV viremia by quantitative PCR CMV DNA test)</outcome>
      <timepoint>36 months post transplant</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adult (&gt;18 years) renal transplant recipient, donor (D) and recipient (R) pretransplant CMV serological status: D+/R-, D+/R+, D-/R+, deceased (including non-heart-beating) or living donor, informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>unknown or D-/R- CMV serostatus pretransplant, allergy to acyclovir, valacyclovir, ganciclovir, and/or valganciclovir, active viral infection at the time of transplantation (including active hepatitis B infection), therapy with systemic antiviral agents &lt;2 weeks prior to transplantation, white blood cell (WBC) count &lt;3.5 x 10exp9/L, platelet count &lt;100 x 10exp9/L, inability to sign informed consent, concomitant inclusion to another clinical trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All subjects indicated to kidney transplantation were considered for inclusion to the trial prior to transplantation. If the patient met inclusion criteria and signed informed consent randomization occurred. Hidden numbered envelops containing the treatment arm were used. Thus the treatment arm was consealed to the researcher until the patient had been included to the trial.</concealment>
    <sequence>Random-number table, 1:1 ratio</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>22/10/2003</anticipatedstartdate>
    <actualstartdate>22/10/2003</actualstartdate>
    <anticipatedenddate>1/05/2006</anticipatedenddate>
    <actualenddate>11/08/2006</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>70</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Tomas Reischig, M.D., Ph.D.</primarysponsorname>
    <primarysponsoraddress>Head of Division of Nephrology,
Department of Internal Medicine I
Charles University Medical School and Teaching Hospital,
alej Svobody 80,
30460 Pilsen
Czech Republic</primarysponsoraddress>
    <primarysponsorcountry>Czech Republic</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Supported by Research Project No. MSM0021620819 'Replacement of and Support to Some Vital Organs' awarded by the Ministry of Education, Youth, and Physical Training of the Czech Republic</fundingname>
      <fundingaddress>Ministry of Education, Youth, and Physical Training of the Czech Republic
Karmelitska  7
118 12 Prague
Czech Republic</fundingaddress>
      <fundingcountry>Czech Republic</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to compare the efficacy, safety and cost of preemptive therapy with vaganciclovir (based on quantitative PCR monitoring) versus universal 3-month prophylaxis with valacyclovir (control group, current standard in our transplant centre).</summary>
    <trialwebsite>not available</trialwebsite>
    <publication>Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. American Journal of Transplantation 2008 Jan;8(1):69-77. 

Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O. Pre-emptive valganciclovir therapy compared with valacyclovir prophylaxis for prevention of cytomegalovirus: 4-year results of a randomized trial in renal transplant recipients. J Am Soc Nephrol 2012, 23(9): 1588-97. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Local Ethics Committee of Charles University Medical School and Teaching Hospital in Pilsen</ethicname>
      <ethicaddress>Local Ethics Committee (director: Prof. J. Finek, M.D., Ph.D.), Charles University Medical School and Teaching Hospital, alej Svobody 80, 304 60 Pilsen, Czech Republic</ethicaddress>
      <ethicapprovaldate>20/07/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>23/06/2003</ethicsubmitdate>
      <ethiccountry>Czech Republic</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Tomas Reischig, M.D., Ph.D.</name>
      <address>Transplant nephrologist, Internal Medicine I, Charles University Hospital, Alej svobody 80, 30460 Pilsen, Czech Republic</address>
      <phone>+420 377103650</phone>
      <fax />
      <email>reischig@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Tomas Reischig, M.D., Ph.D.</name>
      <address>Transplant nephrologist, Internal Medicine I, Charles University Hospital, Alej Svobody 80, 30460 Pilsen, Czech Republic</address>
      <phone>+420 377103650</phone>
      <fax />
      <email>reischig@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tomas Reischig, M.D., Ph.D.</name>
      <address>Transplant nephrologist, Internal Medicine I, Charles University Hospital, Alej svobody 80, 30460 Pilsen, Czech Republic</address>
      <phone>+420 377103650</phone>
      <fax />
      <email>reischig@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Tomas Reischig</name>
      <address>Transplant nephrologist, Internal Medicine I, Charles University Hospital, Alej Svobody 80, 30460 Pilsen, Czech Republic</address>
      <phone>+420377103650</phone>
      <fax />
      <email>reischig@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>